RxDoctor Payments Data

Robert McQueen, MD

Cardiovascular Disease · Morristown, TNNPI 1780780882

Payments from drug & device makers

$17,046in general payments, 2019–2025

Across 450 payments — averaging $37.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Johnson & Johnson$978
  • Actelion Pharmaceuticals US, Inc.$578
  • Abbott$546
  • Novo Nordisk$540
  • plus $5K from 35 others

What the payments were for

  • Travel & lodging$5,71033%
  • Food & beverage$11,22266%
  • Education$1141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,046 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$449,191
Medicare patients
1,610
Services billed
5,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban322$318,387
EntrestoSacubitril/Valsartan115$130,022
XareltoRivaroxaban78$84,634
FarxigaDapagliflozin Propanediol88$84,570
JardianceEmpagliflozin38$48,113
BrilintaTicagrelor16$11,267
Amiodarone Hcl154$3,574
Clonidine23$3,457
Nebivolol Hcl42$2,966
Diltiazem 24hr Er (Cd)Diltiazem Hcl71$2,574
Metoprolol Tartrate375$2,522
Ranolazine ErRanolazine23$2,375
Carvedilol259$1,941
SotalolSotalol Hcl79$1,852
ClopidogrelClopidogrel Bisulfate195$1,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$157$318,387322 claims
NovartisEntresto$426$130,022115 claims
AstraZenecaFarxiga, Brilinta$394$95,837104 claims
Johnson & JohnsonXarelto$978$84,63478 claims
Boehringer IngelheimJardiance$84$48,11338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Morristown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →